Professionals 242 Users Online

Tumour-Induced Osteomalacia Market

Market Study on Tumour-Induced Osteomalacia: Drugs & Supplements Account for Major Market Share

Tumour-Induced Osteomalacia Market Segmented By Drugs and Supplements, Surgery Treatment in Laboratories, Bone Scan, Differential Diagnosis,

Tumour-Induced Osteomalacia Market Outlook (2022-2032)

Worldwide revenue from the tumour-induced osteomalacia market reached US$ 111,372.2 thousand in 2021, with the global market estimated to move ahead at a value CAGR of 2.8% to reach US$ 176,483.9 thousand by the end of 2032.

As assessed by Persistence Market Research, drugs & supplements are expected to hold a market value of around US$ 91,279.4 thousand by 2032. Overall, revenue from tumour-induced osteomalacia (TIO) accounted for 14.2% share of the global rare disease genetic testing market in 2021.

Report Attribute Details

Tumour-Induced Osteomalacia Market Size (2022)

US$ 133,730.9 Thousand

Projected Market Value (2032)

US$ 176,483.9 Thousand

Global Market Growth Rate (2022-2032)

2.8% CAGR

Global Share of Top 5 Countries


Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Tumour-Induced Osteomalacia Market Historical Analysis (2017 to 2021) Vs. Projections (2022 to 2032)

The global market for tumour-induced osteomalacia recorded a high historic CAGR from 2017 to 2021 owing to increasing diagnosis of rare diseases across the world.

To maintain a competitive edge in the market, developers of therapeutics for tumour and bone diseases are concentrating on innovation and introducing novel therapies. For the management of tumour-induced osteomalacia (TIO), some businesses are working on developing Specialty pharmaceuticals while others are on phosphorus, calcium, and vitamin D supplementary products.

Over the projected timeframe, cancer therapies are anticipated to make up over 30% of all preclinical and phase I clinical developments, with pharmaceutical corporations continuing to invest substantially in R&D.

21 new molecular entities have been introduced over the past two years for the treatment of tumour-induced osteomalacia. Due to the complexity of treating tumours with innovative therapeutics, more combination therapies and additional lines of therapies are now being employed, thereby benefiting the market for tumour-induced osteomalacia.

New treatment approaches for previously 'un-druggable' targets, advancements in treatment models for target validation to understand disease pathophysiology, and recent developments in biological therapeutics and orphan drugs have laid the groundwork for a completely new era in rare disease studies.

In addition to being able to diagnose osteomalacia brought on by tumours, genetic technology can also predict the tumour’s potential complications. Osteomalacia is brought on by vitamin D deficiency. Therefore, for successful treatment outcomes, early diagnosis with cutting-edge technology is beneficial.

Future growth of the global tumour-induced osteomalacia market will be driven by the rapidly expanding field of disease therapeutics, which includes small molecules, gene modification, and nucleic acid Labelling therapies.

The global tumour-induced osteomalacia market is thus likely to exhibit steady growth over the decade at a CAGR of 2.8% to reach US$ 176,483.9 thousand by 2032.


Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What’s Enhancing the Stance of Tumour-Induced Osteomalacia Product Manufacturers?

“Vast Clinical Pipeline for Orphan Drug Development”

Though medical research has made significant strides, there are still many key therapies that are yet to be discovered and developed. According to researchers, a key component for the development of therapeutics is addressing unmet medical needs.

Research in cellular biology has advanced over the past two decades, and several fundamental pillars, including small molecules such as inhibitors, can now clearly be identified. These target-specific molecules, which have many advantages over current drug treatments, have not only assisted in comprehending the microenvironment of a cell and its signaling pathways better but have also increased the likelihood of accomplishing clinical benefits, which include improvements in patient tolerability while transcending treatment efficacy.

Drugs to treat tumour-induced osteomalacia have a relatively limited clinical pipeline.

  • For the treatment of tumour-induced osteomalacia, only one drug, Crystiva, manufactured by Ultragenix Pharmaceuticals and Kyowa Hakko Kirin Co., Ltd., along with its small molecule inhibitor Fibroblast growth factor 23 (FGF-23), has been approved.
  • A similar study is being conducted by the National Institutes of Health Clinical Center on the BGJ398 chemical to treat tumour-induced osteomalacia. This research molecule, however, is still in phase 2.

For other pharmaceutical businesses, the chance to invest in novel drug discoveries for such unmet targets is tremendous in a less competitive market.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

What are the Factors Impeding Demand for Tumour-Induced Osteomalacia?

“High-Cost of Treatment and Stringent Regulations”

Treatment of osteomalacia brought on by tumours is relatively expensive. Market expansion is predicted to face significant obstacles as a result of this factor. Depending on the condition and nursing costs, surgery for a tumour can cost anywhere from US$ 50,000 to US$ 100,000 in the U.S., while the total annual cost of all treatments is quantified in billions.

  • Depending on body weight, Burosumab will run to around US$ 160,000 per patient per year for children and US$ 200,000 per patient per year for adults, according to Ultragenyx.

Moreover, there exist barriers to investing in the treatment of rare diseases in the Asian market due to price sensitivity. A majority of people in emerging nations are in the middle-income bracket, making it too expensive for them to incur the cost of treatment for tumour-induced osteomalacia.

Cancer and immunological drug regulations are highly complicated on a global scale. Major market players in care products for rare diseases are dedicated to offering high-quality products and medicines that comply with FDA standards as well as those of other governmental and non-governmental organizations.

Additionally, the manufacturing and selling of orphan medications are subject to strict regulations. This inhibits drug availability, and thereby, market expansion to some extent.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

What Makes the U.S. a Huge Market for Tumour-Induced Osteomalacia?

“Developed Healthcare Infrastructure & Fund Allocation for Rare Disease Therapeutics”

The U.S. accounted for a market share of 66.4% in the global tumour-induced osteomalacia market in 2021.

This high market share is because of the availability of a highly developed research infrastructure, close collaborations between research institutes and hospitals, and programs and funds specially identified for the development of orphan drugs and research into rare diseases.

Will Japan Be a Lucrative Market for Tumour-Induced Osteomalacia?

“Growing Regulatory Approvals for Marketing in the Country”

Japan is set to exhibit a CAGR of around 2.6% in the global tumour-induced osteomalacia market over the forecasted years.

The emergence of new treatment modalities, post-marketing approvals in the country, and the adoption of drugs approved by the FDA and EU are factors responsible for providing traction to the market in Japan.

  • For instance, in August 2022, the European Commission granted Kyowa Kirin authorization to use CRYSVITA® (burosumab) as a therapy for tumor-induced osteomalacia.

What is the Stance of the Indian Market for Tumour-Induced Osteomalacia?

“Large Patient Population and Huge Potential for New Market Entrants”

India held a market share of 2.6% in the global market for tumour-induced osteomalacia market in 2021. The market in India is set to expand at a CAGR of 4.6% over the forecasted years.

India is a developing economy with a large patient base. Manufacturers for drug and therapeutic compounds are presented with a vast opportunity for product inception in this regional market.

Although the competition for pricing in the country may remain high, yet, India poses lucrative prospects for manufacturing collaborations for drug development in the tumour-induced osteomalacia market space.

Category-wise Insights

Which Treatment Accounts for the Most Revenue in the Tumour-Induced Osteomalacia Market?

“Management of Non-Identifiable Tumours”

The drugs and supplements segment held 82% share of the global tumour-induced osteomalacia market in 2021.

Established treatment for TIO is complete surgical excision of the etiologic tumour, which is curative. Tumour recurrence with symptoms is frequently caused by incomplete resection. Between 35 and 40 percent of tumours cannot be located.

Supplementation with numerous daily doses of oral phosphate and active vitamin D analogs is necessary when the tumour cannot be localized and completely removed. Thus, the drugs and supplements segment enjoys the highest market share.

How is the Diagnosis Segment Contributing to Overall Market Expansion?

“Assessment of Symptoms to Evaluate Target Tumour Sites”

The bone scans segment held 80.5% market share at the end of 2021.

Diffuse bone pain is one of the presenting signs of tumour-induced osteomalacia; therefore, before the condition is diagnosed, bone scintigraphy, also known as a bone scan, is generally carried out to identify the source of the pain. Bone scans are quite effective at identifying mineralizing lesions and show increased uptake at injury sites and during ongoing repair. As a result, this market segment commands a large market share.

Competitive Landscape

Leading pharmaceutical companies are putting strong emphasis on partnerships to broaden their product offerings and capture a higher share of the market for drugs used for the diagnosis, treatment, and evaluation of bone diseases.

To maintain a competitive edge in the market, manufacturers in emerging nations are continually investing in research and development activities to design, develop, and introduce new pharmaceuticals and drug combinations, in addition to upgrading their product portfolios.

For instance:

  • In July 2020, Ultragenyx and Kyowa Kirin announced that they had received U.S. FDA approval for Crysvita® (burosumab) for the treatment of TIO.
  • In August 2021, Carbogen Amcis revealed expansion plans in Switzerland and France.

Tumour-Induced Osteomalacia Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

USD Thousands for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • Northern Africa
  • South Africa

Key Market Segments Covered

  • Treatment
  • Diagnosis
  • End User
  • Country

Key Companies Profiled

  • Ultragenyx Pharmaceutical Inc.
  • Dishman Carbogen Amcis Ltd.
  • Teva Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Wockhardt Ltd
  • FDC Limited
  • Lupin Pharmaceuticals
  • Zydus Cadila Healthcare Ltd.
  • Intas Pharmaceuticals Ltd
  • Macleods Pharmaceuticals
  • G.C. Chemie Pharmie Ltd
  • Santiago Life Sciences

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT AnalysisMarket Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Tumour-Induced Osteomalacia Industry Research Segmentation

Tumour-Induced Osteomalacia Market by Treatment:

  • Drugs and Supplements
    • Burosumab -twza
    • Cinarcalcet
    • Calcium
    • Active Vitamin D (Calcitriol/α-calcitriol)
    • Phosphorus
  • Surgery

Tumour-Induced Osteomalacia Market by Diagnosis:

  • Laboratories
    • Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
    • Serum Calcium, PTH, Vitamin D
    • Hyperphosphaturia (Secondary Effects of FDF-23)
    • Hypophosphatemia (Secondary Effects of FDF-23)
  • Bone Scan
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT Scans)
  • Differential Diagnosis
    • Vitamin D Metabolism and Deficiency
    • Osteoporosis
    • Renal Osteodystrophy
    • Others

Tumour-Induced Osteomalacia Market by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Tumour-Induced Osteomalacia Market by Country:

  • U.S.
  • Canada
  • Japan
  • European Countries
  • China
  • Mexico
  • South Korea
  • India
  • Brazil
  • Australia

- Companies Covered in This Report -

  • Ultragenyx Pharmaceutical Inc.
  • Dishman Carbogen Amcis Ltd.
  • Teva Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Wockhardt Ltd
  • FDC Limited
  • Lupin Pharmaceuticals
  • Zydus Cadila Healthcare Ltd.
  • Intas Pharmaceuticals Ltd
  • Macleods Pharmaceuticals
  • G.C. Chemie Pharmie Ltd
  • Santiago Life Sciences

- Frequently Asked Questions -

The global tumour-induced osteomalacia market was valued at US$ 111,372.2 thousand in 2021.

Revenue from tumour-induced osteomalacia treatment is set to increase at 2.8% through 2032.

The tumour-induced osteomalacia market is expected to reach US$ 176,483.9 thousand by 2032.

Hospitals account for a high share in the treatment of tumour-induced osteomalacia.

Ultragenyx Pharmaceutical Inc., Dishman Carbogen Amcis Ltd., and Teva Pharmaceuticals are leading players in this market.

Specialty clinics accounted for a valuation of US$ 41,041.9 thousand at the end of 2021.

Increasing need for comprehensive epidemiological evaluation for rare diseases and emergence of novel disease therapeutics are key factors aiding market growth.

The Japan tumour-induced osteomalacia market is expected to expand at 2.6% CAGR over the decade.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate